Geneva, 23 November 2016 – After seven years as Director General, Eduardo Pisani announced today his decision to leave the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), representing the leading research-based biopharmaceutical companies as well as national and regional industry associations across the world. IFPMA is based in Geneva and has formal consultative status with the United Nations (UN) and its specialized agencies. It engages with international organizations and global health stakeholders including the World Health Organization (WHO), the World Intellectual Property Organization (WIPO), the World Trade Organization (WTO) and the World Bank, on a wide range of public policy interests, including those related to biotechnology and vaccines.
“After seven exciting and challenging years leading the global biopharmaceutical industry it is time to move on to a new challenge”, said Eduardo Pisani. “I am proud of the recognition and trust that IFPMA has built in recent years, thanks to a strong record of accomplishments, in particular on public policy issues, where we constructively engaged with different institutions and organizations, in the fight against neglected tropical diseases, the implementation of the Pandemic Influenza Preparedness Framework, the enhancement of the WHO pre-qualification process, an engagement plan for the prevention and control of non-communicable diseases, and the facilitation of an industry platform on antibiotics. We have also been proactive in collaborating with numerous reputed actors in the global health community[1] on new health partnership programs, thus showing how tangible initiatives can be connected to policy debates”.
IFPMA President and Chairman of the Executive Board and CEO of Merck, Dr Stefan Oschmann underscored Eduardo Pisani’s contribution: “At the helm of IFPMA for the past seven years, Eduardo has overseen a transformation of the federation to reflect and respond to the increasingly dynamic global health policy landscape in which the biopharmaceutical industry operates. He has broadened considerably the scope of IFPMA engagement as the voice of the biopharmaceutical industry in Geneva, and has built a committed team that has been instrumental in establishing collaborative relationships with many stakeholders. Today, thanks to Eduardo’s leadership, IFPMA has a solid foundation to continue pursuing its mission of a sustainable future for patients, society, and industry”. Eduardo Pisani will remain in his role as Director General at IFPMA until 31 January 2017, to ensure a smooth handover and continuity with his successor.
About IFPMA
IFPMA represents the research-based pharmaceutical companies and associations across the globe. The research-based pharmaceutical industry’s 2 million employees research, develop and provide medicines and vaccines that improve the life of patients worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.
Contact
Abigail Jones
acumen public affairs
Tel: +32 475 41 09 76
abigail@acumen-publicaffairs.com
[1] IFPMA Partnerships: http://www.ifpma.org/partners/